About NanoBio Corporation.NanoBio Corporation technology platform focuses the company ‘s lead product candidates are treatments for herpes labialis , onychomycosis , methicillin-resistant Staphylococcus aureus and mucosal vaccines for influenza and hepatitis B. The company’s headquarters and laboratory facilities are read more . In Ann Arbor, Michigan.
The Corporation Announces Positive Phase 1 Clinical Results for the topical treatment of onychomycosisNanoBio Corporation, a biopharmaceutical company developing novel products for the treatment and prevention of severe infections, today announced positive safety data from the Phase 1 clinical development announced study of NB-002, the company drug candidates currently in a phase 2 clinical trial for the topical treatment of onychomycosis.
Top research divergence to plant species reflectedness latitude biodiversity gradient.